Regulus Therapeutics (United States)
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Regulus Therapeutics (United States), United States, covering academic research published from 2008 to 2024. Read More.
Open Access Percentage
52%
Total
Publications
168
Total Open
Publications
87
Total
Citations
22K
Open Access
Percentage
52%
Total
Publications
168
Total Open
Publications
87
Total
Citations
22K
Breakdown
Publisher Open
15%
Both
29%
Other Platform Open
7%
Closed
49%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 35%
25
Hybrid 22%
16
No Guarantees 43%
31
Other Platform Open
Domain 56%
35
Other Internet 42%
26
Institution 31%
19
Public 5%
3
Preprint 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 35 |
DOI | Other Internet | 22 |
Unknown Repository | Other Internet | 5 |
DASH - Digital Access to Scholarship at Harvard | Institution | 4 |
Figshare | Public | 3 |
California Institute of Technology - The Caltech Institute Archives | Institution | 2 |
Washington University School of Medicine - Digital Commons@Becker | Institution | 1 |
Université de Lausanne - SERVAL | Institution | 1 |
University of Southern Denmark - University of Southern Denmark Research Portal | Institution | 1 |
University of Siena - Use Siena air | Institution | 1 |